S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
Log in
NASDAQ:INNT

Innovate Biopharmaceuticals Stock Forecast, Price & News

$1.32
0.00 (0.00 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.23
Now: $1.32
$1.34
50-Day Range
$0.56
MA: $0.94
$1.42
52-Week Range
$0.37
Now: $1.32
$1.67
Volume4.22 million shs
Average Volume525,982 shs
Market Capitalization$54.55 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.39
Innovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.
Innovate Biopharmaceuticals logo

MarketRank

Overall MarketRank

0.48 out of 5 stars

Medical Sector

1383rd out of 1,558 stocks

Pharmaceutical Preparations Industry

596th out of 638 stocks

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:INNT
CUSIPN/A
Phone919-275-1933
Employees8

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.27) per share

Profitability

Net Income$-27,050,000.00

Miscellaneous

Market Cap$54.55 million
Next Earnings DateN/A
OptionableOptionable
$1.32
0.00 (0.00 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive INNT News and Ratings via Email

Sign-up to receive the latest news and ratings for INNT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Innovate Biopharmaceuticals (NASDAQ:INNT) Frequently Asked Questions

How has Innovate Biopharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Innovate Biopharmaceuticals' stock was trading at $0.4715 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, INNT stock has increased by 180.0% and is now trading at $1.32.
View which stocks have been most impacted by COVID-19
.

What stocks does MarketBeat like better than Innovate Biopharmaceuticals?

Wall Street analysts have given Innovate Biopharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Innovate Biopharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Innovate Biopharmaceuticals' earnings last quarter?

Innovate Biopharmaceuticals Inc (NASDAQ:INNT) released its earnings results on Monday, March, 18th. The company reported ($0.11) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.11).
View Innovate Biopharmaceuticals' earnings history
.

Who are some of Innovate Biopharmaceuticals' key competitors?

What other stocks do shareholders of Innovate Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Innovate Biopharmaceuticals investors own include NIO (NIO), Corbus Pharmaceuticals (CRBP), AcelRx Pharmaceuticals (ACRX), (CGC), Iterum Therapeutics (ITRM), SCYNEXIS (SCYX), Micron Technology (MU), Nabriva Therapeutics (NBRV), Neurotrope (NTRP) and Aurora Cannabis (ACB).

Who are Innovate Biopharmaceuticals' key executives?

Innovate Biopharmaceuticals' management team includes the following people:
  • Mr. Sandeep Laumas M.D., CEO & Exec. Chairman (Age 50)
  • Mr. Jay P. Madan M.S., Founder, Pres, Chief Bus. Officer, Interim Principal Fin & Accounting Officer and Director (Age 53)
  • Dr. Christopher P. Prior, Consultant (Age 66)
  • Jerry Gardner M.D., Head of Clinical Strategy
  • Dr. Patrick H. Griffin, Chief Medical Officer (Age 64)

What is Innovate Biopharmaceuticals' stock symbol?

Innovate Biopharmaceuticals trades on the NASDAQ under the ticker symbol "INNT."

How do I buy shares of Innovate Biopharmaceuticals?

Shares of INNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Innovate Biopharmaceuticals' stock price today?

One share of INNT stock can currently be purchased for approximately $1.32.

How big of a company is Innovate Biopharmaceuticals?

Innovate Biopharmaceuticals has a market capitalization of $54.55 million. Innovate Biopharmaceuticals employs 8 workers across the globe.

What is Innovate Biopharmaceuticals' official website?

The official website for Innovate Biopharmaceuticals is www.innovatebiopharma.com.

How can I contact Innovate Biopharmaceuticals?

Innovate Biopharmaceuticals' mailing address is 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615. The company can be reached via phone at 919-275-1933 or via email at [email protected]

This page was last updated on 1/16/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.